Showing results (81-90 of 88) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 88 results.
Arthritis Care & Research|April 19, 2022
Impact of Belimumab on Organ Damage in Systemic Lupus ErythematosusMurray B Urowitz, Cynthia Aranow, Yumi Asukai, et al.
Environmental Science & Technology|January 10, 2023
Contaminant Exposure and Transport from Three Potential Reuse Waters within a Single WatershedJason R Masoner, Dana W Kolpin, Isabelle M Cozzarelli, et al.
Annals of the Rheumatic Diseases|August 19, 2024
Efficacy and safety of sequential therapy with subcutaneous belimumab and one cycle of rituximab in patients with systemic lupus erythematosus: the phase 3, randomised, placebo-controlled BLISS-BELIEVE studyCynthia Aranow, Cornelia F Allaart, Zahir Amoura, et al.
Environment International|December 21, 2022
Bottled water contaminant exposures and potential human effectsPaul M Bradley, Kristin M Romanok, Kelly L Smalling, et al.
Annals of the Rheumatic Diseases|July 24, 2020
Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trialHermine I Brunner, Carlos Abud-Mendoza, Diego O Viola, et al.
The Lancet. Rheumatology|January 27, 2024
Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trialSaira Z Sheikh, Morton A Scheinberg, James Cheng-Chung Wei, et al.
Blood Advances|December 8, 2022
Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AMLStéphane de Botton, Thomas Cluzeau, Carlos Vigil, et al.
Blood Advances|May 7, 2025
Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDSAmy E DeZern, Sylvain Thepot, Stéphane De Botton, et al.
Pageof 9